Ziopharm Oncology (NASDAQ:ZIOP) initiates a 24-subject Phase 1 clinical trial evaluating CD19-specific CAR-T cells in patients with relapsed CD19-positive leukemias and lymphomas.
In the study, the company will use its non-viral Sleeping Beauty genetic engineering technology to infuse the CAR-T the day after electroporation.
The primary objective is safety. Secondary endpoints include safety measures.
The estimated completion date is November 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.